125 filings
Page 4 of 7
8-K
7fx2jvt 620xegnqed
4 Nov 21
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi
5:17pm
8-K
1c3t9n 80426uzmlhflc
4 Nov 21
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
9:00am
8-K
ub920o03795e
25 Oct 21
Other Events
8:05am
8-K
joz 0rxxh
3 Aug 21
Aptose Reports Results for the Second Quarter 2021
4:05pm
8-K
96z4l6w4k1xx8ad1c
11 Jun 21
Aptose Presents Highlights from EHA During Corporate Update Event
8:00am
8-K
l6ky9ha
1 Jun 21
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
4:30pm
8-K
vt9iwfkw
4 May 21
Aptose Reports Results for the First Quarter 2021
4:01pm
8-K
4cprf8gc0eb hgpr8
26 Mar 21
Departure of Directors or Certain Officers
8:30pm
8-K
hrtau1
23 Mar 21
Aptose Reports Results for the Fourth Quarter and Full Year 2020
4:05pm
8-K
56505 xhi
16 Mar 21
Regulation FD Disclosure
7:31am
8-K
xgrijm3ioyf35
7 Dec 20
Aptose Presents Highlights from ASH and Corporate Update Event
6:10am
8-K
codocpzxj3dka3afnq
10 Nov 20
Aptose Reports Results for the Third Quarter 2020
4:04pm
8-K
rmgepkg8yt wgtbq
4 Nov 20
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
10:31am
8-K
brasc9a sbc8qe8h
19 Oct 20
Regulation FD Disclosure
7:05am
8-K
y3q52sz0y0kjt xqk
5 Aug 20
Aptose Reports Results for the Second Quarter 2020
6:05am
8-K
rd9g03i3wf
30 Jul 20
Material Change Report
6:41pm
8-K
nm0ll 2r02
16 Jul 20
Aptose Announces Pricing of Public Offering of Common Shares
4:05pm
8-K
twahp jbypplwn
15 Jul 20
Aptose Announces Proposed Public Offering of Common Shares
4:12pm
8-K
jdcijr y02
29 Jun 20
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
7:12am
8-K
eghrmj j4p8qn5d7
12 Jun 20
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
7:02am